Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

NovoMix 30

- PMLiVE

Novo Nordisk’s Wegovy approved by FDA as oral medication for weight management

Those taking the 25mg pill lost a similar amount of weight as those using injectable Wegovy 2.4mg

- PMLiVE

Novo Nordisk presents new findings on semaglutide in Alzheimer’s disease

While the trials did not meet their primary endpoints, they highlighted important biomarker findings

- PMLiVE

Novo Nordisk reports phase 3 data showing semaglutide reduces liver scarring

Patients with MASH in the ESSENCE phase 3 trial show semaglutide’s potential to improve liver health

- PMLiVE

Pfizer and Metsera agree on merger after bidding war between Pfizer and Novo Nordisk

The Pfizer bid was chosen by Metsera after a concern was raised about US antitrust laws regarding the Novo Nordisk offer

- PMLiVE

Novo Nordisk agrees to lower certain drug prices in the US

The company's semaglutide-based weight-loss drugs will be made available in the US through Medicare and Medicaid

- PMLiVE

Novo Nordisk reports sales growth in 2025 as R&D pipeline advances

Growth driven by increased sales in diabetes and obesity markets

- PMLiVE

EMA reaffirms guidance on paracetamol use during pregnancy

The guidance follows recent US comments about a possible link to autism

- PMLiVE

Johnson & Johnson seeks first EMA approval for icotrokinra for plaque psoriasis

Icotrokinra is a first-in-class, once-daily tablet for moderate-to-severe plaque psoriasis

- PMLiVE

Novo Nordisk to cuts 9,000 jobs in an effort to streamline its operations

The transition will help the company meet the rising global demand in the obesity market

- PMLiVE

EMA orphan drug designation given to ReAlta for graft-versus-host disease therapy

This follows preliminary results from the company's ongoing phase 2 trial

- PMLiVE

Novo Nordisk’s Alhemo approved by FDA for expanded haemophilia use

The rare bleeding disorder affects approximately 800,000 people globally

- PMLiVE

Novo Nordisk appoints Maziar Mike Doustdar as president and CEO

Doustdar has most recently been serving as Novo’s executive vice president of international operations

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links